Skip to main content

Debate on safety of e-cigarettes continues

Debate on safety of e-cigarettes continues
09 Dec 2014

Opposing views on the potential impact of electronic cigarettes on public health are published in the open access journal BMC Medicine. The commentaries, by two experts, differ in their views on the topic but are united in their call for a rational discussion based on evidence.

The authors examine the WHO’s recommendations earlier this year. One recommendation was that smokers should not use e-cigarettes and has now been withdrawn, and the other is that policymakers should implement their strict regulation, which is still in force.

In one of the commentaries, Peter Hajek, professor and director of the Tobacco Dependence Research Unit at Queen Mary University of London, says: “There are currently two main products competing for smokers’ custom. One, the conventional cigarette, is responsible for disease and premature death in a substantial proportion of its users. It also continues to recruit new customers from among non-smoking children who try it. The other, the e-cigarette, is orders of magnitude safer. On current evidence it only appeals to smokers and generates negligible rates of regular use among non-smoking children who try it. Which one would you prefer your nicotine addicted father to use? And if your children were to try a nicotine product, which of these two would you prefer that they lay their hands on?”

He continues: “For a negative impact, e-cigarettes use would have to generate an increase in use of cigarettes. This appears a highly improbable concern. There is no precedent for a safer technology to increase the use of its less safe competitor.”

In her commentary Charlotta Pisinger, associate professor, senior researcher at the Research Centre for Prevention and Health, Glostrup Hospital, Denmark, offers an opposing view: “When we compare with a conventional cigarette, the most harmful legal product on the market, everything seems harmless. For a smoker reluctant to stop smoking the e-cigarettes will most probably be a less harmful alternative - but we cannot focus on these smokers only…The potential health benefits obtained by some smokers must out-weigh the potential harm by use of ex- and never-smokers, of smokers who intended to quit but switched to e-cigarettes, of smokers’ dual use and of eventual re-normalization of smoking.”

She concludes: “Most probably e-cigarettes are less harmful than conventional cigarettes, but they can hardly be called safe. Consequences of e-cigarettes use must be viewed in a long-term public health perspective, including both smokers and non-smokers.”

Much of the current research in this area can suffer from methodological limitations, significant conflicts of interest and inconsistent results. To address these issues so that evidence-based decisions can be made, BMC Medicine has launched an article collection on the topic. The commentaries by Peter Hajek and Charlotta Pisinger are the first in a series of debates in this special article collection. Further critiques from invited experts will be published in due course on a spectrum of topics about e-cigarettes, from research agendas, health policies and regulation, to psychiatric and public health outcomes.


Media Contact
Shane Canning
Media Manager
BioMed Central
T: +44 (0)20 3192 2243
M: +44 (0)78 2598 4543

Notes to Editor

1. Commentary
Electronic cigarettes have a potential for huge public health benefit.
Peter Hajek
BMC Medicine 2014, 12:225

The article is available at journal website here.

Why public health people are more worried than excited over e-cigarettes
Charlotta Pisinger
BMC Medicine 2014, 12:226

The article is available at journal website here.

Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.

2. BMC Medicine is the flagship medical journal of the BMC series, publishing original research, commentaries and reviews that are either of significant interest to all areas of medicine and clinical practice, or provide key translational or clinical advances in a specific field.

3. BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.